Stocks / DXCM
DXCM stock forecast
DEXCOM INC · Healthcare · Medical Devices
The model's rating
Outperform
DXCM is rated Outperform as of September 29, 2026: its medium-term return forecast is above the middle of the stocks the model scores, but outside the top fifth.
Create a free account to compare any two stocks; the numeric score is part of Premium.
DXCM is not among the 20 largest holdings published for 2026 Q4. See the portfolio
DXCM against the S&P 500
| Period | DXCM | S&P 500 (SPY) |
|---|---|---|
| 1 month | -5.2% | -0.3% |
| 3 months | +25.3% | +2.5% |
| Year to date | +30.0% | +12.7% |
| 1 year | +28.2% | +15.7% |
Total return, dividends included.
Key numbers
| Price | $86.29 |
| Market cap | 32.56 Billion |
| P/E (trailing 12 months) | 33.3 |
| P/S (trailing 12 months) | 6.5 |
| P/B (latest quarter) | 10.7 |
| Gross margin | 62.5% |
| Net profit margin | 20.1% |
| Return on equity | 36.2% |
| Beta | 0.7 |
As of July 30, 2026.
DXCM and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| STE | STERIS PLC | 20.48 Billion | Greatly Underperform | DXCM vs STE |
| ZBH | ZIMMER BIOMET HOLDINGS INC | 16.94 Billion | Underperform | DXCM vs ZBH |
| EW | EDWARDS LIFESCIENCES CORP | 49.75 Billion | Outperform | EW vs DXCM |
| ALGN | ALIGN TECHNOLOGY INC | 10.33 Billion | Greatly Outperform | |
| PODD | INSULET CORP | 9.05 Billion | Greatly Outperform | |
| BSX | BOSTON SCIENTIFIC CORP | 63.26 Billion | Greatly Outperform | BSX vs DXCM |
Questions
What does the Upfront Investment model say about DXCM?
The model rates DEXCOM INC (DXCM) "Outperform" as of September 29, 2026, which means its medium-term return forecast is above the middle of the stocks the model scores, but outside the top fifth. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the DXCM rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is DXCM in the Upfront Investment model portfolio?
DXCM is not among the 20 largest holdings published for 2026 Q4.
The rating is the output of a statistical model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.